Small ruminant lentivirus genotype B and E interaction: Evidences on the role of Roccaverano strain on reducing proviral load of the challenging CAEV strain. by Bertolotti L et al.
                             Elsevier Editorial System(tm) for Vaccine 
                                  Manuscript Draft 
 
 
Manuscript Number:  
 
Title: Small ruminant lentivirus genotype B and E interaction: evidences 
on the role of Roccaverano strain on reducing proviral load of the 
challenging CAEV strain  
 
Article Type: Regular Research Articles max 3000 words 
 
Keywords: Small ruminant lentivirus, genotype E, Roccaverano, 
experimental infection, immunization strategy 
 
Corresponding Author: Dr. Sergio Rosati,  
 
Corresponding Author's Institution: Faculty of veterinary medicine 
 
First Author: Luigi Bertolotti 
 
Order of Authors: Luigi Bertolotti; ramses Reina; Maurizio Mazzei; Silvia  
Preziuso; Michele Camero; Daniele Demeneghi; Giovanni Perona; Giuseppe 
Bertoni; Sergio Rosati 
 
Abstract: Live attenuated vaccines provide the most consistent protective 
immunity in experimental models of lentivirus infections. In this study 
we tested the hypothesis that animals infected with a naturally 
attenuated small ruminant lentivirus field strain of genotype E may 
control a challenge infection with a virulent strain of the caprine 
arthritis encephalitis virus (CAEV-CO). Within genotype E, Roccaverano 
strain has been described as low pathogenic since decreased arthritic 
pathological indexes were recorded in Roccaverano-infected animals 
compared to animals of the same breed infected with genotype B strains. 
Moreover, under natural conditions, animals double-infected with genotype 
B and E appear less prone to develop SRLV-related disease, leading to a 
putative protective role of Roccaverano strain. Here we present evidence 
that goats experimentally infected with the avirulent genotype E SRLV-
Roccaverano strain control the proviral load of a pathogenic challenge 
virus (CAEV-CO strain) more efficiently than naïve animals and appear to 
limit the spread of histological lesions to the contralateral joints. 
 
Suggested Reviewers: Yahia Chebloune 
INRA France 
ychebloune@lyon.inra.fr 
 
Stephen Valas 
ANSES Laboratoire de Niort  
stephen.valas@anses.fr 
 
Jan Brinkhof 
Animal Health Service Deventer 
j.brinkhof@gddeventer.com 
 
Barbara  Blacklaws 
 Department of Veterinary Medicine, Cambridge Veterinary School 
bab2@cam.ac.uk 
 
Jodi Craigo 
University of Pittsburgh 
craigoj@cvr.pitt.edu 
 
 Valgerdur Andrésdóttir 
 Institute for Experimental Pathology, University of Iceland 
valand@hi.is 
 
 
Opposed Reviewers:  
 
 
Dear Editor 
I would like to submit the manuscript entitled “Small ruminant lentivirus genotype E and B 
interaction: evidences on the role of Roccaverano strain (Genotype E) on reducing proviral load of 
the challenging CAEV strain (Genotype B)” for publication on Vaccine. It describes a double 
infection in goats using a field strain of small ruminant lentivirus naturally deleted for dUTPase and 
VPR-like gene (Roccaverano strain) and antigenically distinct from Caprine Arthritis Encephalitis 
Virus (CAEV), which was used as challenge strain. Results demonstrate that proviral load of CAEV 
in double infected animals is statistically lower than in single infected group and suggest the 
potential application of Roccaverano strain as live attenuated vaccine for control of SRLV in goat 
population, heavily infected with pathogenic CAEV strains. We believe that this study would be of 
interest not only for scientists involved in small ruminant lentivirus research. Thank you in advance 
for your consideration. 
The corresponding author 
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Abstract 
Live attenuated vaccines provide the most consistent protective immunity in experimental models 
of lentivirus infections. In this study we tested the hypothesis that animals infected with a naturally 
attenuated small ruminant lentivirus field strain of genotype E may control a challenge infection 
with a virulent strain of the caprine arthritis encephalitis virus (CAEV-CO). Within genotype E, 
Roccaverano strain has been described as low pathogenic since decreased arthritic pathological 
indexes were recorded in Roccaverano-infected animals compared to animals of the same breed 
infected with genotype B strains. Moreover, under natural conditions, animals double-infected with 
genotype B and E appear less prone to develop SRLV-related disease, leading to a putative 
protective role of Roccaverano strain. Here we present evidence that goats experimentally infected 
with the avirulent genotype E SRLV-Roccaverano strain control the proviral load of a pathogenic 
challenge virus (CAEV-CO strain) more efficiently than naïve animals and appear to limit the 
spread of histological lesions to the contralateral joints. 
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Abstract 
Live attenuated vaccines provide the most consistent protective immunity in experimental models 
of lentivirus infections. In this study we tested the hypothesis that animals infected with a naturally 
attenuated small ruminant lentivirus field strain of genotype E may control a challenge infection 
with a virulent strain of the caprine arthritis encephalitis virus (CAEV-CO). Within genotype E, 
Roccaverano strain has been described as low pathogenic since decreased arthritic pathological 
indexes were recorded in Roccaverano-infected animals compared to animals of the same breed 
infected with genotype B strains. Moreover, under natural conditions, animals double-infected with 
genotype B and E appear less prone to develop SRLV-related disease, leading to a putative 
protective role of Roccaverano strain. Here we present evidence that goats experimentally infected 
*Manuscript
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with the avirulent genotype E SRLV-Roccaverano strain control the proviral load of a pathogenic 
challenge virus (CAEV-CO strain) more efficiently than naïve animals and appear to limit the 
spread of histological lesions to the contralateral joints. 
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Introduction 
Small ruminant lentiviruses (SRLV) are distributed around the world causing a multisystemic 
disease in sheep and goats leading to production losses as well as to consequences in animal trade 
and welfare. Target organs typically, the lungs, udder, carpal joints and the central nervous system, 
are affected by inflammatory process characterized by a dense cellular infiltrate of mononuclear 
leukocytes, mainly lymphocytes and, to a lesser extent, B cells, plasmatic cells and macrophages 
the latter being the SRLV target cell in vivo [1-3]. Control is mainly based on serological diagnosis 
and culling of the seropositive animals. However, detection of antibodies is affected by antigenic 
heterogeneity among SRLV genotypes, which makes serological testing an inaccurate control 
method if heterologous diagnostic antigen is employed [4, 5]. 
SRLV are genetically divided into five genotypes [6-8]. Among them, it is well known the 
association between the genotype B and the caprine arthritis encephalitis disease, causing a threat 
on animal welfare and in milk production of small ruminants. In contrast, the lastly described 
genotype E, was first isolated in few local Roccaverano breed goats in Piedmont, Italy, where no 
SRLV related clinical signs were reported by breeders or practitioners. Histopathological score was 
also reduced, when evaluated under natural and experimental conditions (Grego, unpublished 
observations). These findings together with natural deletions of the dUTPase subunit of the pol gene 
and the vpr-like gene, within viral genome, led us to tentatively term Roccaverano strain, as low 
pathogenic caprine lentivirus [9, 10]. In addition, the Roccaverano strain was identified in a flock in 
which animals were found co-infected with the pathogenic CAEV-like genotype B, with no 
apparent development of SRLV-related disease. Current opinion among local breeders and 
practitioners is the breed resistance of Roccaverano goat to CAEV infection, compared to Alpine 
and Saanen breeds. However, Roccaverano breed goats infected by field genotype B strains did 
develop arthritis [5]. In the light of the discovery of genotype E infection, preexisting to the 
introduction of CAEV-like strains in this local population, a new approach should be taken into 
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account to explain breed resistance: could genotype E infection act as live attenuated vaccine, able 
to induce resistance to superinfection versus heterologous strains? 
We recently evaluated the immunological parameters in goats experimentally infected with 
Roccaverano strain using homologous and heterologous antigens. Results clearly indicated that 
humoral and T-cell proliferation responses were strictly detected against recombinant antigens from 
the homologous genotype, while cytotoxic-T-lymphocyte (CTL) activity was not strain specific, 
being surprisingly higher against genotype B infected antigen presenting cells [10]. Thus CTL 
activity is likely the sole adaptive immune response which could be associated to protection against 
heterologous strain. Following these experiments, in this study we have explored the potential 
protective role of genotype E in vivo under strictly controlled conditions by infecting goats with 
Roccaverano strain followed by a challenge with pathogenic CAEV-CO strain. Results indicate that 
previous infection with genotype E results in a decreased proviral load of the challenge strain, 
acting itself as a potential natural prevention strategy to control SRLV infection. 
 
Materials and Methods 
Cells and Viruses 
Caprine peripheral blood mononuclear cells (PBMC) were obtained from SRLV-free animals and 
derived macrophages (BDM) were allowed to differentiate for 9-15 days as described [9]. BDMs 
were used to propagate and titrate Roccaverano strain. Goat synovial membrane primary cell line 
was used to propagate and titrate CAEV Cork strain. 
Low pathogenic SRLV strain Roccaverano (genotype E, subtype E1) was isolated and characterized 
in previous studies [11]. The pUC9kb-CAEV [12] and pCAEVLTR-cat [13] plasmids containing 
two fragments that allow reconstitution of replication-competent CAEV-CO virus upon co-
transfection of primary goat synovial membrane cells (GSM) were kindly supplied by Dr. R. Vigne 
(Marseille, France). 
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Animals  
Animals from a certified SRLV-free herd formed by Roccaverano breed goats as previously 
described [5], were used in this study. A total of 22 female goats were purchased as weaned kids 
and introduced into the experimental facilities at the Faculty of Veterinary Medicine, University of 
Turin, Grugliasco, Italy (CISRA FMV UNITO) 18 months before the experimental infection. 
Animals were tested monthly and found consistently negative for SRLV antibodies using genotype 
A, B and E-derived antigens for a one-year period. Animals included in experimental and control 
groups had similar age distribution, ranging from 9 to 24 months. During the experiment, a total of 
22 goat kids born between 243 and 355 days post challenge. In detail, 7 kids born from animals 
infected with Roccaverano strain, 11 from animals infected with CAEV-CO and 4 from uninfected 
animals. 
Experiments were carried out in compliance with the relevant National legislation on experimental 
animals and animal welfare, upon authorization by the competent authority (Italian Ministry of 
Health-Directorate General Animal Health-Office VI; permit no. 07/2009B). 
 
Experimental design 
Animals were divided into three groups. Group A included 8 animals that were subjected to 
experimental infection with Roccaverano strain inoculated intra-tracheally with 2 ml of 
2.5x10
5
TCID50/ml. After 4 months, animals were challenged with CAEV-CO through direct 
inoculation of 0.5 ml of 10
6
 TCID50/ml per animal in the right carpal joint, after removal of an equal 
volume of synovial fluid. Group B included 8 animals infected with the CAEV-CO strain at the 
same time, dose and challenge method as group A. Group C included 6 healthy animals, as control 
group. 
EDTA blood samples were obtained in all groups 15 days prior to infection (-15), at weekly interval 
until day 49, and bi-weekly until day 132, corresponding to the day of the challenge. After the 
CAEV-CO infection, EDTA blood samples were collected from all animals at weekly interval until 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 
 
day 169, bi-weekly until day 205, and then every 4-6 weeks until the end of experiment which 
lasted over one year after challenge with a total of 28 time points. From each blood sample plasma 
was collected after centrifugation and stored at -20ºC for serological analysis and buffy coats were 
recovered, resuspended in PBS and stored at -20ºC until DNA extraction for PCR studies. 
After parturition, colostrum was sampled and analyzed for proviral load as well as antibodies and 
blood samples were collected from all kids bi-weekly until the end of the experiment. 
 
Serological analysis 
In order to evaluate the serological response against each infecting strain, a genotype-specific and a 
strain specific ELISA tests were applied. The first employs a recombinant P16-25 fusion protein 
derived from genotype B and E, which has been proven in previous study to discriminate between 
SRLV genotype B or E infection [5]. The second ELISA test is based on strain specific SU5 
synthetic peptides which have been successfully described as specific and precocious (early) marker 
of infection [14, 15]. Synthetic peptide sequences of Roccaverano and CAEV-CO strains used in 
the second ELISA test (strain specific) were QVRAYTYGVIEMPTGYETPTIRRR and 
KVRAYTYGVIEMPENYAKTRIINRK respectively. All animals were tested at each time point 
and seroconversion against the two variants of the same antigen was independently monitored.  
 
DNA extraction and proviral load quantification 
DNA was isolated from buffy coats with DNeasy Blood and Tissue kit (Qiagen, Germany) and 
quantified by fluorimetry with Picogreen dsDNA Quantitation kit, (Invitrogen, Carlsbad, CA). Two 
sets of strain-specific primers and probes were designed with Beacon Designer 7 (Premier Biosoft 
International) to set up a duplex q-PCR targeting pol sequences. Primer and probe sequences are 
reported in Table 1. PCR reactions were carried out in triplicate with Quantitech Multiplex PCR kit 
(Qiagen) in a volume of 25 µl with 200nM each primer, 300 nM probe and 5 µl of DNA. After an 
initial activation at 95°C for 15 min, reactions were subjected to 50 cycles of 94°C for 15 sec and 
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60°C for 1 min. Negative controls were included in each assay, as well as serially diluted positive 
controls allowing quantification through estimations on a standard curve. In more details, two 
different plasmids carrying Roccaverano and CAEV-CO pol gene fragments spanning the real-time 
amplicons were prepared. The former included a 3,309 bp insert (nucleotides 3782 to 7090 along 
Roccaverano genome) while the latter carried a 453 bp fragment, corresponding to nucleotides 1589 
to 2131 in CAEV-CO genome. Serial dilutions from10
6
 to 5 copies/reaction) of both plasmids were 
included in each assay to generate standard curves. 
The coefficient of variation (COV) of the proviral copy number per reaction of the three replicas for 
each DNA template was calculated. A threshold value of 0.28 was established for DNAs having 
more than 10 copies per reaction and outliers were excluded from further analysis. No COV 
analysis was applied to DNA samples carrying less than 10 copies per reaction. Proviral load values 
were expressed as the average copy number per microgram of template DNA. 
 
T cell proliferation 
Measurement of T cell proliferation against homologous and heterologous antigens was carried out 
as described elsewhere [10] . Briefly, PBMCs prepared by buffy coat centrifugation on Ficoll 
gradient were plated in 96-well plates at a concentration of 10
5 
cells/well in RPMI-1640 medium 
(Sigma–Aldrich Company Ltd) supplemented with 2mM L-glutamine, 50 µM beta-
mercaptoethanol, 100 U penicillin and 100 µg streptomycin/ml, 10% FBS (RPMI 10). PBMCs were 
incubated in quadruplicate with recombinant heterologous (genotype B) or autologous (genotype E) 
P25 antigen, or GST (as negative control) at equimolar amounts. Antigens were plated at 25, 12 and 
6 µg/ml in 200 µl and after a five-day incubation, cells were labelled with 1 µCi of [
3
H] thymidine
 
(Amersham) for 5 h. Incorporated radioactivity was determined using a Filter Cell Harvester 1540 
(Wallac) and a Beta counter. Proliferation was measured as a stimulation index (SI) normalizing 
incorporated radioactivity in P25 wells with that obtained in the GST wells. The SI was calculated 
for each antigen using the formula SI = cpm with antigen/cpm with GST protein. 
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An individual animal was considered to show positive T cell reactivity if the SI was greater than 3 
in at least two antigen dilutions. 
 
Clinical and histopathological examination 
In order to determine the development of clinical arthritis, the circumference ratio between carpus 
and the contralateral metacarpus (c/m) was monitored. As commonly known, ratios above 1.8 
indicated the presence of clinical arthritis [16]. 
Following euthanasia of experimental goats, samples from the left and the right carpal joints were 
collected and fixed in buffered formalin for 48 hours. Two synovial tissue samples from each 
sample were embedded in paraffin for histopathology. Four-micron sections were stained with 
haematoxylin and eosin staining (H&E) according to routine procedures. The slides were observed 
blindly by two independent pathologists monthly for three times. Each time, five pictures at 20X 
were evaluated from each sample. On the basis of the enlargement of the synovial lining cell layer, 
the density of the resident cells and the inflammatory infiltrate, histological lesions were blindly 
recorded as no lesion, mild, moderate or severe lesions. The mean value of the three lesion scores 
was considered as the final score. Final lesion score of the left and the right synovial samples were 
compared. 
 
Statistical analysis 
Real time PCR sensitivity and specificity were analyzed with Rotor-Gene software version 1.7 
(Qiagen). Blood proviral load, clinical and histopathological lesion scores from groups A and B 
were analyzed and compared using Wilcoxon rank-sum test at each time point, considering α=0.05. 
Fisher‟s exact test was applied for T cell proliferation frequencies of positive animals. All statistical 
tests were performed using R statistical software [17]. 
 
Results 
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Serological response  
Seroconversion against Roccaverano and CAEV-CO strains was evaluated using indirect ELISA 
containing p16-25 recombinant protein and SU5 synthetic peptide derived from each of the two 
genotypes (Fig 1). 
In animals belonging to the group A, serological response was mounted exclusively against 
homologous p16-25 antigen within 14 and 104 days. Peaks were reached at 44 and 72 days p.i. and 
afterwards decreased transiently to become consistently positive upon 141 days drawing the typical 
two-phase curve. After CAEV-CO challenge, group A developed antibodies against genotype B 
antigen, thus becoming positive versus both genotypes (Fig 1). 
Seroconversion in animals from Group B was readily observed after 2-3 weeks after challenge 
against homologous antigen and remained well above detection limit till the end of the experiment. 
As expected, seroconversion against genotype E antigens was not generally observed with few time 
points close to the threshold limit (Fig 1a and 1c).  
Seroconversion against SU5 antigen reflected that to p16-25. Group A showed early seroconversion 
against both genotypes post-challenge while group B showed seroconversion exclusively against 
CAEV-CO SU5-derived antigen. 
Seroconversion in goat kids was evaluated against genotypes B and E using both P16-25 and SU5 
ELISA tests employing either plasma or colostrum as sample source. Both ELISA tests showed a 
slow decrease of passive immunity without apparent seroconversion in both groups up to 16 weeks 
after birth (Fig. 2). 
 
Proviral load quantification 
The linear range of amplification of the duplex q-PCR was determined from 10
6
 to 5 copies per 
reaction using Roccaverano and CAEV-CO plasmid dilutions. The amplification of the standard 
dilutions showed linearity over six orders of magnitude (1x10
6
 to 10 copies/reaction) with a target 
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specificity of 100%. The assay was able to amplify at least one replica of the standard dilution 
containing 5 copies. The mean amplification efficiency of both targets was 97,0%.  
The proviral load of both strains showed considerable variation during the time course of the 
experiment. Considering the CAEV strain, according to figure 3, differences between animal groups 
were slightly significant at 317 days post challenge (Wilcoxon Sum Rank test p < 0.10) and 
progressively CAEV proviral load became significantly higher in animals belonging to the group B 
than ones belonging to the group A during the three following time points (day#364 p<0.05, 
day#407 p<0.05, day#462 p<0.05). At the end of the experiment an increasing CAEV proviral load 
in group A animals, resulted in non-significant differences between groups. 
Four group A and seven group B goats gave birth to seven and eleven kids respectively. Colostrum 
was sampled from the mothers and blood was collected from the kids during four months. None of 
the kids born from group A goats carried the proviral CAEV genome, which was detected in three 
of the eleven kids born to group B goats. This result could suggest a possible difference in CAEV 
transmission to the progeny caused by the genotype E interference but, considering the small 
sample size, no statistical analyses can be carried out. 
 
T cell proliferation 
As previously shown, infection with genotype E resulted in a genotype specific T cell proliferation 
[10]. Challenge with CAEV-CO induced a broader response showing positive reactions versus both 
genotype derived antigens (data not shown). 
Infection with CAEV-CO (group B) induced similarly a strain specific response with no detectable 
reaction against genotype E derived antigen. 
 
Clinical and histopathological examination 
Arthritic pathological score, expressed as the ratio between circumferences of the right carpal joint 
and the contralateral metacarpal one, was calculated for each animal at each time point. All animals 
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showed ratio levels below 1.8 throughout the whole experiment and no differences were recorded 
among groups (Wilcoxon Sum rank test p > 0.05 at each time point). 
Right carpal joints (inoculation site) were generally more affected than left ones as expected. 
Precisely, in 5 goats belonging to the group A, lesions in the right synovial membrane samples were 
more severe than in the left, while in 2 animals no difference was observed. In the group B, 2 goats 
had right synovial membrane lesions more severe than those present in the left synovial membrane, 
while in 4 animals no difference was observed. No synovitis was observed in both right and left 
carpal joints of the group C animals (Table 2). Two out of three animals from group A showing 
severe lesions in the right carpal joint displayed no lesion in the left. In group B this tendency was 
observed only from severe to low degree of lesion (Table 2). In two cases (2631 and 2634) the 
comparison between the left and the right synovial membrane samples was not possible because the 
synovial lining cell layer was not adequately present in two out of the four samples collected from 
each animal. 
 
Discussion 
Attenuated virus vaccines are currently used for the prevention of a wide range of viruses such as 
Influenza virus [18], SIV [19], EIAV [20], chicken pox or yellow fever [21] conferring different 
degrees of protection. Among the strategies applied to immunize against HIV or SIV lentiviral 
infections, those based on live attenuated viruses have reached the highest levels of protection [22]. 
There are also several examples of effectiveness within lentiviral animal infections such as Feline 
immunodeficiency virus (FIV) and Equine infectious anemia virus (EIAV). FIV vaccines based on 
modified attenuated live viruses have been compared with subunit vaccines delivered as plasmid 
DNA or as protein, inducing moderate levels of cellular immunity and significant antibody 
responses conferring increased protection rates [23]. Regarding EIAV, among the various strategies 
explored, including immunizations based on attenuated viruses, inactivated virus particles, protein 
subunits, DNA vaccines, and live vectors, the highest level of protection was achieved when using 
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attenuated viruses, likely due to the continuous antigen exposure and optimized maturation of the 
immune response. However, there is an inverse relationship between the level of protection and the 
level of attenuation, indicating that a minimal replication rate is needed for eliciting protective 
immune responses [21]. In the early 70‟s an attenuated strain (DLV120) obtained by in vitro 
passages in donkeys, conferred protection against EIAV challenge [24], and was extensively used in 
China with promising results [20]. 
Immunization against SRLV has been explored deeply in the last decades with occasionally 
disappointing results. Various strategies have been applied including artificially attenuated whole 
virus [25-27], subunit vaccines supplied as protein or as expression plasmids or recombinant viruses 
[28-31]. CAEV deletions of vif, essential for viral replication [32], induced weak responses with no 
protection whereas CAEV tat-, replication competent [33] conferred some degree of protection but 
still induced inflammatory lesions, further confirming the inverse relationship between attenuation 
and protection [34]. 
Early approaches within DNA immunization were carried out with env and tat encoding plasmids 
and conferred some degree or protection related to Th1-biased response [35-37]. The newest 
approaches employed, in a series of vaccination experiments, DNA plasmids encoding gag and env 
viral genes and recombinant modified Vaccinia Ankara as inocula together with the employment of 
immunologic adyuvants such as IFN-gamma or B7 costimulatory molecules [31]. Immunity was 
stimulated enough to control viremia and proviral load in tissues but not in terms of reduced lesion 
development, with an increased inflammation in target tissues, probably masking a competent 
immune response [28, 29, 31]. These SRLV vaccine experiments confirmed that virus-specific 
immune responses are a double edged sword that can contribute to either control or enhance virus 
replication or disease. In all previous vaccination studies, a common experimental design was the 
antigenic homology between vaccine antigen and challenge strain, leading to conclude that humoral 
response, with different degree of stimulation recorded in the different vaccine strategies, may play 
a deleterious role in protection.  
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In this study, we infected goats with the naturally attenuated strain Roccaverano from the genotype 
E of SRLV, in order to induce protection against both the proviral load and the development of 
SRLV-related pathology. Goats were double infected with Roccaverano and CAEV-CO strains with 
an interval of 4 months (Group A) or single-infected with CAEV-CO (Group B). Serological 
analysis showed that, although a normal antibody response was elicited in both groups according to 
the strains used, a clear type specific reactivity was obtained, being the pre-challenge of group A 
reactive exclusively against genotype E antigen, becoming reactive in the post-challenge period 
against both antigens. Group B as expected showed reactivity against genotype B antigen. Similar 
results were obtained in lymphoproliferation assay, leading to suppose that, if any protection 
occurs, this may not be related to a Th2 response, which is thought to be non-effective to control the 
infection [30, 38]. 
Goats infected with genotypes E and B indeed showed lower proviral loads than goats single 
infected with genotype B strongly indicating that the Roccaverano infection may have induced a 
sustained immune response able to control genotype B proviral load and possibly, target tissues 
colonization. Proviral load and lesion development, have been associated in a wide number of 
SRLV infection studies [16, 39-41]. Assuming this relationship, histopathological results were in 
line with proviral load ones, since dissemination of lesions was lower in Roccaverano infected 
animals. Even so, macroscopic lesions (arthritic pathological score) evaluation did not show evident 
differences. Explanations for this lack of contralateral affectation in group B, may include 
differences between reference strain CAEV-CO and field strains causing arthritis in Roccaverano 
goats. 
Infection with Roccaverano and CAEV-CO strains induce exclusively homologous antibody and T 
proliferative responses, but conferred protection against heterologous infection likely due to CTL 
activity as our previous results strongly suggest [10]. 
Finally, we provided clear evidence that both viruses and antibodies against both SRLV strains 
passed to the progeny, although genotype B was not detected in kids raised by group A mothers 
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(Fig 2; Table 3). This decreased viral flow to the progeny could reflect the lower proviral load 
found in the mothers, thus reducing viral transmission. Probably due to the short period of 
observation of the kids, we had not chance to evaluate the seroconversion against the viruses, but 
we only detected the decreasing of maternal antibody response. 
The main goal of a vaccine is to achieve protection not only towards homologous strains but also 
against heterologous infection, this goal would be even more important in controlling lentiviral 
infections including SRLV, that are probably the most widely distributed lentivirus and one of the 
most heterogenous. Genotype E Roccaverano strain infection could be of extensive application not 
only in naïve goats but also in goats already infected with pathogenic genotype B. Roccaverano 
infection may open new approaches to naturally immunize against SRLV being the first naturally 
attenuated vaccine conferring protection in terms of reduced viral load and, possibly, reduction of 
viral colonization and lesion development.  
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Figure 1. Seroconversion to type specific antigens. Seroconversion against SRLV genotype E 
Roccaverano strain (a: p16-25 antigen; c: SU5 antigen) and against SRLV genotype B CAEV-Co strain (b: 
p16-25; d: SU5) in animals belonging to the group A (circles and solid line) and to the group B (squares and 
dashed line). Seroconversion is indicated as the average of reactivity among animals and it is expressed as 
the percentage against the homologous positive control. Vertical solid lines represent the standard error of 
the mean, calculated among animals belonging to the same group and within the same collection time. 
Vertical dotted line represents the time of challenge (day=133). 
 
Figure 2. Seroconversion in the progeny. Seroconversion against SRLV genotype E Roccaverano strain (a: 
p16-25 antigen; c: SU5 antigen) and against SRLV genotype B CAEV-Co strain (b: p16-25; d: SU5) in kids 
born from animals belonging to the group A (circles and solid line) and to the group B (squares and dashed 
line). Seroconversion is indicated as the average of reactivity among animals and it is expressed as the 
percentage against the homologous positive control. Vertical solid lines represent the standard error of the 
mean, calculated among animals belonging to the same group and within the same collection time. 
 
Figure 3. CAEV Proviral load. Mean number of provirus copies in blood of animals belonging to the group 
A (circles and solid line) and B (squares and dashed line). Vertical solid lines represent the standard error of 
the mean, calculated among animals belonging to the same group and within the same collection time. 
Vertical dotted line represents the time of challenge (day=133). Statistical differences are reported on the x 
axis („°‟ Wilcoxon Rank Sum test p < 0.10; „*‟ Wilcoxon Rank Sum test p < 0.05) 
 
  
Table 1. Primers and probes 1 
Primer or probe Sequence (5'-3') 
Nucleotide 
position 
Amplicon 
length (bp) 
Roccaverano_Fw AACACAGGAAGAGAAATAGTGAGG 3863-3886 
114 Roccaverano_Rev GAGCGATCTTGCATCTTGGTG  3976-3956 
Roccaverano_Probe FAM-CCAGTGTTCTTCTTCCGCCTCCGG-BHQ-1 3949-3926 
CAEV-Co_Fw AAAGAATGCAGAGGAAAGAGAGAC  1763-1786 
106 CAEV-Co_Rev GGTGCTGAAGTTATTCCATAGGAG  1868-1845 
CAEV-Co_Probe HEX-CGGACGGCACCACACGTATCCC-BHQ-1  1841-1820 
 2 
3 
Table(s)
  
Table 2. Synovitis observed in right (R) and left (L) carpal joints. 4 
group animal n. right (R) left (L) 
Comparison 
R vs L 
A 50011 low no > 
A 2638 moderate low > 
A 2629 severe low > 
A 2633 severe no > 
A 2634 unclassified moderate - 
A 50013 low low = 
A 2588 low low = 
A 50010 severe no > 
B 2637 low low = 
B 2635 severe low > 
B 50015 low low = 
B 50012 severe low > 
B 50014 low low = 
B 2631 moderate unclassified - 
B 2587 low low = 
C 7686 no no = 
C 7837 no no = 
C 7841 no no = 
 5 
6 
  
Table 3. Proviral load of Roccaverano (RV) and CAEV viral strains in mothers, colostrum and 7 
kids. 8 
Group Goat N° Virus Viral load (Wk0 to Wk51) Colostrum  Kids  
A 
2588 
RV + + + + + + + + - + + + + + + 
CAEV - + + - + + - - - - + - - - - 
2633 
RV + + + - - + - + + + + - + -  
CAEV + + - - - + - + - + - - - -  
50010 
RV + + + + + + + + + + + - -   
CAEV - - - + + + - + - - - - -   
50011 
RV + - + + + + + + + + + + +   
CAEV - - - + - - - + - - + + -   
B 
2587 CAEV nd + + + + + + + + + + - - +  
2631 CAEV nd + + - + + + + + + + - - -  
2635 CAEV nd + + + + + + + + + + - -   
2637 CAEV nd + - - - - - - + - + - -   
50012 CAEV - - + + + + + + + + + + + +  
50014 CAEV - + - - - + - + - - - - -   
50015 CAEV - + + - + + + + + + + - -   
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